ASCO23 Meeting

https://www.nejm.org/doi/full/10.1056/NEJMoa2301665? https://www.nejm.org/doi/full/10.1056/NEJMoa2304594? https://www.nejm.org/doi/full/10.1056/NEJMoa2304194? https://www.nejm.org/doi/full/10.1056/NEJMoa2303269? https://www.nejm.org/doi/full/10.1056/NEJMoa2303379? https://www.nejm.org/doi/full/10.1056/NEJMoa2302983?   Studio EV-103 Enfortumab + Pembrolizumab https://meetings.asco.org/abstracts-presentations/218065 Studio CHRYSALIS  Amivantamab + Lazertinib https://meetings.asco.org/abstracts-presentations/218855 Studio DISCOVARY  Darolutamide https://meetings.asco.org/abstracts-presentations/218558 Studio ARASENS Darolutamide https://meetings.asco.org/abstracts-presentations/222950 Larotrectinib https://meetings.asco.org/abstracts-presentations/218863 https://meetings.asco.org/abstracts-presentations/224722 Erdafitinib https://meetings.asco.org/abstracts-presentations/218016 Dorstalimab https://meetings.asco.org/abstracts-presentations/218587